Appropriate biomarkers can accurately predict and monitor early efficacy and indicate emerging resistance to anlotinib. Fortunately, several clinical trials have identified circulating biomarkers that predict anlotinib activity, specifically activated circulating endothelial cells (aCECs) and EGFR-sensitizing mutations or T790M mutation.
Categories
Anlotinib Biomarkers (1)
In this article we will discuss Anlotinib Biomarkers (1)